<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="130951">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01670877</url>
  </required_header>
  <id_info>
    <org_study_id>201209135</org_study_id>
    <nct_id>NCT01670877</nct_id>
  </id_info>
  <brief_title>Neratinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer</brief_title>
  <official_title>A Phase II Study of Neratinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II study will test cancer to see if it has a HER2 mutation and, if so, see how
      HER2 mutated cancer responds to treatment with neratinib.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Overall clinical activity (CR+PR+SDâ‰¥6months) of neratinib in patients with metastatic HER2 breast cancer that carry HER2 mutation</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Response and progression will be evaluated in this study using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1).  Changes in the largest diameter (unidimensional measurement) of the tumor lesions and the shortest diameter in the case of malignant lymph nodes are used in the RECIST criteria. Eighty percent confidence interval (CI) will be calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS of patients treated with neratinib</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The time to progression or death will be listed, and the progression-free survival (PFS) will be estimated using Kaplan-Meier product limit method.  For all the enrolled patients, the number and percentage of patients with HER2 mutation will be presented, and its 95% CI will also be calculated. The agreement for the occurrence of HER2 mutation in paired primary and metastatic sites will be described using contingency tables and assess by McNemar test. The association of the presence of HER2 mutation with histology subtype (invasive lobular vs invasive ductal cancer), tumor grade, tumor staging at initial diagnosis (I vs II or III vs IV), and progression-free survival (PFS) will be assessed using Fisher's exact test, Mann-Whitney rank sum test, or log-rank test as appropriate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlate the presence of HER2 mutation with histology subtype (invasive lobular vs. invasive ductal cancer), tumor grade (grade 1-2 vs 3), tumor staging at initial diagnosis (I vs. II or III vs. IV), disease free survival in HER2- breast cancer.</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">29</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Neratinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive neratinib PO daily on days 1-28. Each cycle is 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neratinib</intervention_name>
    <arm_group_label>Neratinib</arm_group_label>
    <other_name>PF-05208767</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Pre-registration:

          -  Histologically or cytologically confirmed HER2-negative (0 or 1+ by IHC or
             non-amplified by FISH) breast cancer that is stage IV.

          -  There is no limitation on the number of prior lines of systemic therapy.

          -  Presence of measurable or non-measurable disease by RECIST 1.1.

          -  At least 18 years of age.

          -  ECOG performance status &lt; or = 2.

          -  Adequate organ function as defined below within 8 weeks of pre-registration:

               -  Serum creatinine &lt; or = 1.5 x ULN

               -  Total bilirubin &lt; or = 1.5 x ULN )in case of known Gilbert's syndrome, &lt; 2 x ULN
                  is allowed)

               -  AST and ALT &lt; or = 3 x ULN

          -  Able to understand and willing to sign an IRB approved written informed consent
             document.

        Note: HER2 mutation testing may be performed while the patient is receiving active
        systemic therapy for metastatic breast cancer so that the result can be used to determine
        eligibility for study drug therapy in the future.

        Exclusion Criteria for Pre-registration:

          -  Testing for LVEF is not required for pre-registration, but patient must not have a
             recent LVEF &lt; LLN or have symptoms of congestive heart failure.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, unstable angina pectoris, cardiac arrhythmia, or psychiatric
             illness/social situations that would limit compliance with study requirements.

          -  Acute or currently active hepatic or biliary disease requiring antiviral therapy
             (with the exception of Gilbert's syndrome, asymptomatic gallstones, liver metastases,
             or stable chronic liver disease per investigator assessment).

          -  History of significant cardiac disease, cardiac risk factors, or uncontrolled
             arrhythmias.

          -  Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs
             resulting in dyspnea at rest.

        Inclusion Criteria for Registration

          -  Tumor tissue tested positive for HER2 mutation.

          -  ECOG performance status &lt; or = 2.

          -  Adequate organ function as defined below within 2 weeks of registration:

               -  ANC &gt; or = 1.5 x 10^9/L

               -  Platelet count &gt; or = 100 x 10^9/L

               -  Serum creatinine &lt; or = 1.5 x ULN

               -  Total bilirubin &lt; or = 1.5 x ULN (in case of known Gilbert's syndrome, &lt; 2 x ULN
                  is allowed)

               -  AST and ALT &lt; or = 3 x ULN

          -  The patient must have completed radiation therapy and be at least 1 week from the
             last systemic chemotherapy administration, with adequate recovery of bone marrow and
             organ functions, before starting neratinib.

          -  Presence of disease progression on the most recent disease evaluation.

          -  Patients with known brain metastasis are eligible, but must have received radiation
             and be off steroids and stable (without evidence of disease progression by imaging or
             exam) for 3 months.

          -  QTc interval &lt; or = 0.450 seconds within 2 weeks of registration.

          -  LVEF &gt; or = institutional ILLN within 4 weeks of registration.

          -  Women of childbearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control, abstinence) prior to study entry and
             for the duration of study participation.  Should a woman become pregnant or suspect
             she is pregnant while participating in this study, she must inform her treating
             physician immediately

          -  Able to understand and willing to sign an IRB approved written informed consent
             document.

          -  There is no limitation on the number of prior lines of systemic therapy.

        Exclusion Criteria for Registration:

          -  Currently receiving any other investigational agents or systemic cancer therapy.

          -  Currently taking medications and herbal or dietary supplements that are strong
             cytochrome P450 (CYP) 3A4 inducers or inhibitors.  The washout period must have been
             completed prior to the start of neratinib if the patient was taking any of these
             agents.  If unavoidable, patients taking CYP3A4 inhibitors should be monitored
             closely.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Acute or currently active/requiring antiviral therapy hepatic or biliary disease
             (with the exception of patients with Gilbert's syndrome, asymptomatic gallstones,
             liver metastases, or stable chronic liver disease per investigator assessment).

          -  Pregnant and/or breastfeeding.

          -  History of significant cardiac disease, cardiac risk factors, or uncontrolled
             arrhythmias.

          -  Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs
             resulting in dyspnea at rest.

          -  Experiencing grade 2 or greater diarrhea.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cynthia Ma, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cynthia Ma, M.D., Ph.D.</last_name>
    <phone>314-362-9383</phone>
    <email>cma@dom.wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andres Forero-Torres, M.D.</last_name>
      <phone>205-975-2837</phone>
      <email>aforero@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Andres Forero, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Debu Tripathy, M.D.</last_name>
      <phone>323-865-3962</phone>
      <email>tripathy@usc.edu</email>
    </contact>
    <investigator>
      <last_name>Debu Tripathy, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford Medicine Cancer Institute</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Pegram, M.D.</last_name>
      <phone>650-723-5801</phone>
      <email>mpegram@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Pegram, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melody Cobleigh, M.D.</last_name>
      <email>melody_cobleigh@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Melody Cobleigh, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute, Harvard University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Freedman, M.D.</last_name>
      <phone>617-632-6876</phone>
      <email>rachel_freedman@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Rachel Freedman, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Hayes, M.D.</last_name>
      <phone>734-615-6725</phone>
      <email>hayesdf@umich.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Hayes, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Luke's Cancer Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy J Pluard, M.D.</last_name>
      <phone>816-932-6005</phone>
      <email>tpluard@saint-lukes.org</email>
    </contact>
    <investigator>
      <last_name>Timothy J Pluard, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Ma, M.D., Ph.D.</last_name>
      <phone>314-362-9383</phone>
      <email>cma@dom.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew Ellis, MB., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ron Bose, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shashikant Kulkarni, M.S.., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Naughton, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Sorscher, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rama Suresh, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adel Tabchy, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Foluso Ademuyiwa, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chau Dang, M.D.</last_name>
      <phone>646-888-4554</phone>
      <email>dangc@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Shanu Modi, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chau T Dang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisa Carey, M.D.</last_name>
      <phone>919-843-6814</phone>
      <email>Lisa_Carey@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Charles Perou, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lisa A Carey, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke Cancer Institute</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Blackwell, M.D.</last_name>
      <phone>919-681-0874</phone>
      <email>kimberly.blackwell@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Kimberly Blackwell, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Erin Macrae, M.D.</last_name>
      <phone>614-366-8541</phone>
      <email>erin.olson@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Erin Macrae, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BC Cancer Agency</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1L3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karen Gelmon, M.D.</last_name>
      <email>kgelmon@bccancer.bc.ca</email>
    </contact>
    <investigator>
      <last_name>Karen Gelmon, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Bedard, M.D.</last_name>
      <phone>416-946-4534</phone>
      <email>philippe.bedard@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Philippe Bedard, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 2, 2014</lastchanged_date>
  <firstreceived_date>August 17, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
